ARTICLE | Company News
PegBio, Pfizer form diabetes partnership in China
December 13, 2016 11:08 PM UTC
Pfizer Inc. (NYSE:PFE) granted PegBio Co. Ltd. (Suzhou, China) rights in Greater China to a glucokinase (GCK, GK) agonist to treat diabetes. The partnership is part of a Pfizer strategy to use local partners to advance medicines addressing unmet needs. The partners did not respond to inquiries about the program.
PegBio said financial terms were not disclosed and that the GCK program has completed Phase IIa development...
BCIQ Target Profiles